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ABSTRACT
This study was undertaken to evaluate the anti-inflammatory, anti-
hyperalgesia and antioxidant activity of the hydro-alcoholic stem bark 
extract of Macaranga barteri (MBE). The carrageenan-induced foot 
oedema and Hargreaves thermal hyperalgesia models in rats were 
used to examine the anti-inflammatory and anti-hyperalgesic effects 
respectively. The 2, 2-diphenyl-2-picrylhydrazyl hydrate (DPPH) free 
radical scavenging and total antioxidant capacity assays were used 
to determine the antioxidant activity. In a curative protocol, MBE (30, 
100, 300 mg kg-1, p.o.) dose dependently and significantly inhibited 
carrageenan-induced foot oedema by 37.01 ± 13.08, 53.01 ± 9.87 
and 64.11 ± 9.05% respectively (ED
50
 = 89.37 ± 7.52 mg kg-1). The 
extract further attenuated cutaneous hyperalgesia by prolonging paw 
withdrawal latencies towards an external heat stimulus with an ED
50
 
of 105.5 ± 4.22 mg kg-1. MBE was found to possess a total antioxidant 
capacity of 531.62 ± 10.98 mg g-1 dry weight (Gallic acid equivalent) 
and scavenged DPPH free radicals with an IC
50 
of 19.45 ± 1.46 µg/mL. 
The results provide the first report on the anti-inflammatory, analgesic 
and antioxidant activity of M. barteri stem bark and partly justify its 
traditional use in the management of inflammation and pain. This 
could be attributed to phytochemicals such as tannins, terpenoids, 
sterols, coumarins and flavonoids which were identified in preliminary 
phytochemical studies of the stem bark.
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INTRODUCTION 
Inflammation is a complex defensive and protec-
tive response of living tissues to injury, irrita-
tion or infection and is accompanied by typical 
symptoms of pain, swelling, redness and fever.1 
Although defensive in nature, the complexity of 
events as well as the mediators released during an 
inflammatory process often result in the induction 
or aggravation of painful disease conditions such 
as rheumatoid arthritis, osteoarthritis, inflam-
matory bowel disease, colitis and hepatitis. These 
diseases can cause disability, reduce the quality 
of life and impose a huge social and economic 
burden on individual victims and the society 
as a whole.2 The current medications available 
for the treatment of inflammatory conditions 
include  non-steroidal anti-inflammatory drugs 
(NSAIDs), disease modifying anti-rheumatic 
drugs (DMARDs), opioids and corticosteroids 
which are unfortunately associated with adverse 
effects limiting their use in several cases. Due 
to this, the search for other alternative effective 
treatment options has occupied many research 
groups for the past years.3 
Macaranga barteri Müll.-Arg is a common 
species of the family Euphorbiaceae distributed 
in the arid forests and grassy savannahs of trop-
ical Africa. In Ghana, it is locally called ‘opam 
kokoo’ (Akan) or ‘opesare’ (Akyem) alluding to 
the plant’s habit of occurring in depleting forests.4 
Ethnobotanical surveys report the use of the 
powdered leaves and bark or a decoction of these 
parts as a vermifuge and febrifuge in Nigerian and 
Congolese folk medicine. In Sierra Leone, the leaf 
decoction is used to treat sexually transmitted 
infection, as a laxative and haematinic. Together 
with other Macaranga species, it is also used to 
relieve persistent cough, bronchitis, stomatitis, 
gastric ulcer, dysentery, swelling and arthritis.5 
In previous scientific reports, the leaf extract of 
M. barteri showed remarkable antimicrobial, 
antioxidant and anti-diabetic activity as well as 
the ability to protect the gastric mucosa against 
gastric injury.6-8 Moreover, a bioactive polyoxy-
genated ellagitannin isolated from the stem bark 
called macabarterin significantly inhibited the 
production of superoxides in a human neutrophil 
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respiratory burst assay indicating potential 
anti-inflammatory activity.9 Consequently, it 
suggests that the stem bark may be a potential 
source of therapeutic agents in the treatment of 
inflammatory conditions. There is however no 
report on the anti-inflammatory or analgesic 
effects of M. barteri stem bark. This study therefore 
investigated the anti-inflammatory activity of the 
hydro-ethanolic stem bark extract of M.  barteri 
and its ability to attenuate cutaneous hyperalge-
sia. The total antioxidant capacity and free radical 
scavenging activity of the stem bark extract were 
also investigated.
MATERIALS AND METHODS
Plant collection and authentication
The stem bark of M. barteri was collected from a 
semi-arid forest in Kwahu Asakraka, a town in 
the Eastern Region of Ghana in August, 2018. 
Verification of the plant material was carried out 
at the Herbal Medicine Department, Faculty of 
Pharmacy and Pharmaceutical Sciences, KNUST, 
Ghana by Dr. George Henry Sam. A voucher spec-
imen with the code KNUST/HM/2017/M016 was 
deposited at the herbarium of the faculty. 
Preparation of extract
The stem barks were cleared of foreign material, cut 
into pieces, air dried and ground into fine powder. 
One kilogram of the powdered stem bark was 
extracted by cold maceration with 70 % ethanol 
for 72 h. The extract obtained was concentrated on 
a rotary evaporator under reduced pressure and 
temperature and further dried in the hot air oven 
at 50 °C to obtain a dark brown powdery extract 
subsequently referred to as MBE or ‘the extract’ in 
this study. A yield of 10.4 %w/w was obtained. 
Phytochemical Screening
Various classes of plant secondary metabolites 
were screened for following previously established 
methods.10
Drugs and chemicals
Diclofenac sodium, dexamethasone and morphine 
hydrochloride were obtained from Phyto-Riker, 
Accra, Ghana and Carrageenan from Sigma-
Aldrich Inc., St. Louis, MO. USA. The extract was 
reconstituted in normal saline (NaCl, 0.9%) for oral 
administration.
Animals
Male Sprague–Dawley rats weighing approxi-
mately 200 ± 50 g were bought from Noguchi 
Memorial Institute for Medical Research, 
University of Ghana and transferred to the animal 
house of the Pharmacology Department, Kwame 
Nkrumah University of Science and Technology 
(KNUST). The animals were kept in groups of 
five in stainless steel cages with wood-shavings 
as bedding. Animals had access to local commer-
cial rodent chow (Agricare Ltd, Kumasi, Ghana) 
and water  ad libitum. The laboratory conditions 
were maintained at a temperature of 25 ± 1°C, 
relative humidity 60–70%, and 12-h light-dark 
cycle. The National Institute of Health Guidelines 
for the Care and Use of Laboratory Animals 
(Directive 2010/63/EU; Animal Care and Use 
Committee,  1998) were followed during experi-
mental procedures. Approval was also sought from 
the Pharmacology Department Ethics Committee, 
KNUST.
Acute toxicity test
The acute toxicity testing was performed to deter-
mine the doses of extract that will be safe for 
administration to rats without causing any adverse 
effect or death. The assay was performed following 
a previously described method.11 Briefly, male and 
female Sprague-Dawley rats were grouped into four 
with five rats in each group. After an overnight fast 
(water ad libitum), the rats were orally administered 
300, 1000 and 3000 mg kg-1 of extract or normal 
saline (0.9%; 10 mL/kg) and monitored closely for 
gross behavioral changes or death for 0, 15, 30, 60, 
120 and 180 minutes and also 24 h and 14 days after 
extract administration. 
Carrageenan-induced rat paw edema
The anti-inflammatory activity of MBE was evalu-
ated by the carrageenan-induced paw oedema assay 
in rats with few modifications.12 Briefly, inflamma-
tion was induced in the right hind paw by injection 
of 100 μL of carrageenan suspension (2% w/v) into 
the sub-plantar tissue after the baseline reading of 
the foot diameter was taken for all animals. The 
various groups of animals received saline (10 mL 
kg-1 of 0.9 % NaCl i.p), MBE (30-300 mg kg-1, p.o), 
diclofenac (10-100 mg kg-1, i.p) or dexametha-
sone (1-10 mg kg-1, i.p) 1 h for o.p. and 30 min 
for i.p. post-carrageenan injection. Increase in 
foot volumes was then recorded by measuring the 
foot diameters with an electronic calliper (model: 
Z22855, Milomex Ltd., Bedfordshire, UK) at hourly 
intervals for six hours. The percentage change in 
paw oedema from time 0 h was calculated using the 
equation [(D t - D 0)/D 0 × 100] where D 0 is the paw 
diameter pre carrageenan administration (time 0 h) 
and D t is the paw diameter post carrageenan 
132 Discovery Phytomedicine 2019; 6(3): 130-137. doi: 10.15562/phytomedicine.2019.104 www.phytomedicine.ejournals.ca
Macaranga barteri stem bark ... Evelyn Asante-Kwatia, et al.
administration (time t h). Each test result was calcu-
lated as a mean of three repeated measurements. 
Carrageenan-induced thermal hyperalgesia
The anti-hyperalgesic effect of MBE was evaluated 
using the Hargreaves thermal hyperalgesia model 
with few modifications.13 On the day of experiment, 
the animals (five in each group) were individually 
placed in Plexiglas cages with a plain glass under-
neath and were allowed to acclimatize to the testing 
chamber for 20 min. The baseline paw withdrawal 
latency (PWL) for each animal towards a radiant 
heat source was determined before the experi-
ment. Inflammation was evoked by a subcutaneous 
intra-plantar injection of 100 μL carrageenan (2 % w/v) 
into the right hind paw. The groups of animals then 
received vehicle (10 mL kg-1  of 0.9% NaCl, i.p), 
MBE (30-300 mg kg-1, p.o), diclofenac (10-100 mg 
kg-1, i.p) or morphine (1-10 mg kg-1, i.p), 1 h for 
o.p. and 30 min for i.p. post-carrageenan injection. 
Hyperalgesia was assessed by placing the inflamed 
paw above a radiant heat stimulus and the PWL 
was measured with an Analgesia Meter (Model 336, 
IITC Life Science Inc., Woodland Hills, CA, USA) 
actuated with an automatic timer. The heat source 
was set to a low intensity and a cut-off time of 25 s 
was set to prevent damage to paw tissues. The paw 
withdrawal latency (PWL) was defined as the time 
required for the rat to lift the paw away from heat 
source. The PWLs were determined every hour for 
5 h, starting 2 h after carrageenan injection. Each 
test was calculated as a mean of three repeated 
measurements. 
Antioxidant Activity
2, 2-diphenyl-1-picrylhydrazyl (DPPH) free radical 
scavenging assay
The radical scavenging effect of M. barteri stem 
bark extract (MBE) was determined following a 
previously described method.14 MBE (100 µL each) 
at a concentration range of 500 to 7.8 μg mL-1, was 
mixed with 300 µL of DPPH (20 mg L-1 in metha-
nol). The mixture was incubated for 30 min in the 
dark, after which the absorbance of residual DPPH 
was measured at 517 nm on a Cecil CE 7200 spec-
trophotometer, (Cecil Instrument Limited, Milton 
Technical Centre, England). Gallic acid and meth-
anol were used as positive and negative controls 
respectively. The experiments were carried out in 
triplicate and results presented as the mean of three 
values. The percentage free radical scavenging 
activity was calculated according to the follow-
ing equation: % DPPH inhibition = [(Abs sample- 
Abs control)/ Abs control × 100].
Where ‘Abs sample’ and ‘Abs control’ are absor-
bance of sample and control respectively.
Total Antioxidant Capacity (TAC)
The total anti-oxidant capacity of MBE was deter-
mined using the phosphomolybdenum method 
as previously described.15 Briefly, 100 µL of seri-
ally diluted MBE extract (500 - 7.8 μg mL -1) was 
added to 1 mL of a reagent solution consisting 
of Ammonium molybdate (4 mM), disodium 
hydrogen phosphate (28 mM) and sulphuric acid 
(6 mM) and incubated at 95°C for 90 minutes. The 
cooled mixture (200 μL) was transferred into a 
microtitre plate and the absorbance at 695 nm was 
measured. A standard calibration curve was gener-
ated from Gallic acid (500 - 7.8 μg mL -1) and used 
as the reference standard (Figure. 6). The experi-
ments were performed in triplicate and expressed 
as Gallic acid equivalent (GAE) in mg/g of dried 
extract.
Statistical analysis
All data were presented as the mean ± standard 
error mean (S.E.M, n = 5). Raw data for the carra-
geenan-induced inflammation and thermal hyper-
algesia tests was calculated as the percentage change 
in maximum possible effect (% MPE). Two-way 
repeated measures analysis of variance (ANOVA) 
was used to analyze the time-course curves followed 
by Dunnett's  post hoc  test. The total anti-inflam-
matory or analgesic score for the treatment group 
was calculated as the area under the curve (AUC). 
The differences in AUCs were compared using 
1-way ANOVA complemented Newman–Keuls test 
with drug treatment as a between-subjects factor. 
An iterative computer least squares method, with 
the following non-linear regression (3-parameter 
logistic) equation was used to evaluate the ED50s: 
Y = a + (b –a)/ 1 + 10 Log ED50˗ X
Where, X denotes logarithm of dose and Y 
represents response. Y starts at ‘a’ (the bottom) and 
goes to ‘b’ (the top) with a sigmoid shape. GraphPad 
Prism for Windows version 8.0 (GraphPad 
Software, San Diego, CA, USA) was used for all 
statistical analyzes and a P value less than 0.05 was 
considered statistically significant.
RESULTS
Phytochemical screening
Phytochemical analysis of the stem bark of 
M. barteri revealed major classes of secondary 
metabolites presented on Table 1.
Acute toxicity
Administration of 3000 mg of MBE resulted in 
no toxic signs, changes in gross behaviour or 
death during the study period and after 14 days of 
observation.
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Inhibition of carrageenan-induced paw 
oedema 
Figure 1 shows the effect of MBE, dexamethasone 
and diclofenac on carrageenan-induced rat paw 
oedema observed over a period of 6 hours. From 
the time course curves (Figure. 1 A, B, C), injec-
tion of 100 µL of 2 %w/v carrageenan resulted in 
moderate inflammation which caused an increase 
in paw volume peaking at about 2 -3 h, after which 
a slow decrease in oedema was observed. Two-way 
ANOVA statistics (treatment × time) revealed that 
the administration of MBE (30, 100, 300 mg kg-1) 
significantly (F (3, 16) = 17.4, p < 0.0001) reduced 
the increase in paw volume in a dose-dependent 
manner. The total oedema recorded for each treat-
ment group was expressed in arbitrary units as the 
area under curve (AUC) of the time-course curves 
(Figure. 1 D, E, F). The percentage reduction of total 
paw oedema for all treatment groups is presented 
on Table 2. Diclofenac (10, 30,100 mg kg-1) signifi-
cantly (F (3, 16) = 23.74, p < 0.0001) suppressed the 
increase in paw volume dose dependently. The 
effect of dexamethasone (1, 3, 10 mg kg-1), was 
more significant than diclofenac (F (3, 16) =21.14, 
p < 0.0001). A non-linear regression analysis of the 
dose-response curves (Figure. 2) gave an ED50 value 
of MBE as 89.37 ± 7.52 mg kg-1 which was about 
5 times less potent than diclofenac (ED50 = 17.52 ± 
4.28 mg kg-1) and about 49 times less potent than 
dexamethasone (ED50 = 1.82 ± 2.28 mg kg-1).
Inhibition of inflammation-induced thermal 
hyperalgesia 
Subcutaneous intra-plantar injection of 2 %w/v 
carrageenan into the right hind paws of rats resulted 
in inflammation accompanied by cutaneous 
hyperalgesia to thermal stimuli approximately 1 h 
after carrageenan injection, peaked around 2-3 h 
and subsided afterwards. In the negative control 
group, hyperalgesia was observed as shorter 
paw withdrawal latency towards the thermal 
heat stimulus compared with baseline measure-
ments. On the contrary, administration of MBE 
(30–300 mg kg-1 p.o.), significantly (F (3, 16) = 
26.31; p < 0.0001) and dose dependently atten-
uated the thermal hyperalgesia being recorded 
as a longer paw withdrawal latency compared 
to the vehicle treated group (Figure. 3 A, D). 
The anti-nociceptive effect produced by all treat-
ment groups was calculated as percentage maxi-
mum possible effect (% MPE) and also expressed 
in arbitrary units as the area under curve (AUC) 
of the time course curves (Figure. 3 D, E, F). 
Diclofenac (10-100 mg kg-1, p.o.) and morphine 
Table 1 Phytochemical screening of M. barteri stem bark
Secondary metabolite Results
Tannins +
Saponins -
Alkaloids +
Flavonoids +
Coumarins +
Sterol +
Triterpene +
(+): detected, (˗): not detected
Table 2 Percentage inhibition of carrageenan induced paw oedema
MBE DICLO DEXA
Dose  
(mg kg-1)
30 100 300 10 30 100 1 3 10
% 
Inhibition
37.01 ± 
13.08
53.01 ± 
9.87
64.11 ± 
9.05
52.78 ± 
6.95
57.93 
±12.50
64.67 ± 
4.35
49.89 ± 
10.04
57.54 ± 
14.39
67.93 ± 
3.40
** *** **** **** **** **** *** **** ****
Data is presented as mean ± S.E.M. (n =5); ****P < 0.0001; *** P < 0.001; **P < 0.01, *P < 0.05 compared to vehicle-treated group
Table 3  IC50 of MBE and Gallic acid in DPPH radical scavenging assay
Sample IC50 ± SD µg/mL 
MBE 19.45 ± 1.46
Gallic acid 7.32 ± 1.36
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(1–10 mg kg-1, i.p.) also dose-dependently inhibited 
the hyperalgesia (Figure. 3 B, E: diclofenac: F (3, 16) = 
50.04, p < 0.0001; Figure. 3 C, F: morphine: F (3, 16)= 
41.55; p < 0.0001), but were more potent than 
MBE. From non-linear regression analysis of the 
 dose-response curves (Figure. 4), the ED50 value 
for MBE was determined to be 105.5 ± 4.22 mg kg-1 
which was less potent than diclofenac (ED50 = 
Figure 1  Effect of MBE (30 - 300 mg kg-1 p.o.), 
diclofenac (10 – 100 mg kg-1 i.p.) and 
dexamethasone (1– 10 mg kg-1 i.p.) on 
the time course curves (A, B, C) and total 
oedema response (D, E, F) in carrageen-
an-induced paw oedema in rats. Data is 
presented as mean ± S.E.M. (n =5); ****P 
< 0.0001; *** P < 0.001; **P < 0.01, *P < 
0.05 compared to vehicle-treated group 
(1-way ANOVA followed by Bonferroni’s 
post hoc test).
Figure 3  Effect of extract (30 - 300 mg kg-1 p.o.), 
diclofenac (10 – 100 mg kg-1 i.p.) and 
morphine (1– 10 mg kg-1 i.p.) on the 
time course curves (A, B, C) of carra-
geenan-induced thermal hyperalgesia 
in rat in the Hargreaves-model and 
the AUC (D, E, F). Data is presented as 
mean ± S.E.M. (n = 5); ****P < 0.0001; 
*** P < 0.001; **P < 0.01, *P < 0.05 com-
pared to vehicle-treated group (1-way 
ANOVA followed by Bonferroni’s post 
hoc test). [black circles = MBE; black 
squares = Diclo; black triangles = Dexa]
Figure 4  Dose response curves for extract 
(30-300 mg kg-1 p.o.), diclofenac 
(10-100 mg kg-1 i.p.) and morphine 
(1-10 mg kg-1 p.o.) on carrageenan 
induced thermal hyperalgesia in rats. 
[black circles = MBE; black squares = 
Diclo; black triangles = Morphine]
Figure 2  Dose response curves for MBE 
(30-300  mg kg-1 p.o.), diclofenac 
(10-100 mg kg-1 i.p.) and dexamethasone 
(1-10 mg kg-1 p.o.) on carrageenan 
induced thermal hyperalgesia in rats.
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32.13 ± 3.21 mg kg-1) and morphine (ED50 = 3.68 ± 
1.81 mg kg-1). 
Antioxidant Activity
In the DPPH radical scavenging assay, MBE 
exhibited a maximum radical scavenging effect 
of 87.04  ± 1.84 % corresponding to an IC50 value 
of 19.45  µg  mL-1. The effect was concentration 
dependent (Figure. 5). The reference compound, 
Gallic acid was about thrice as more effective as the 
extract with 86.68 ± 0.90 % radical scavenging effect 
at 100 µg mL-1 and an IC50 of 7.32 µg mL-1 (Table 3). 
The total antioxidant capacity was measured as 
milligram of Gallic acid equivalent (GAE) per gram 
of the dried extract. The extract showed increasing 
total antioxidant capacity with increasing concen-
tration (Figure. 7). MBE had a GAE of 531.62 ± 
10.98 mg g-1 dry weight of the extract which implies 
that a gram of the extract would have an antioxi-
dant capacity equivalent to that of about 531 mg of 
Gallic acid. 
DISCUSSION
The stem bark of Macaranga barteri is used tradi-
tionally for the treatment of conditions charac-
terized by inflammation and pain in African folk 
medicine.9 This study investigated the anti-inflam-
matory, anti-hyperalgesia and anti-oxidant effects 
of the 70% hydro-alcoholic extract of the stem bark.
In a curative treatment regimen, oral adminis-
tration of MBE caused a significant dose-depen-
dent reduction in carrageenan-induced rat paw 
oedema validating the use of the plant in treatment 
of inflammatory conditions. The development of 
oedema following the injection of carrageenan has 
been shown to be a biphasic event beginning with 
the release of mediators such as serotonin, hista-
mine and bradykinin (1-3 h) which causes increased 
permeability of post-capillary venules, exudation 
of fluids to the site of injury and eventually visi-
ble oedema of the affected tissue.16 Subsequently, 
inducible isoforms of cycloygenase (COX-2) and 
nitric oxide synthase (iNOs) cause the release of 
prostaglandins (PGs) and NO respectively sustain-
ing the oedema in the latter phase of inflammation 
(3-5 h). Though the mechanism of action of MBE 
is yet to be established, this study reveals that 
M. barteri stem bark extract possibly acts through 
the inhibition of the production and/or action of 
one or more of these inflammatory mediators.
The nociceptive threshold of inflamed paws 
in control and MBE-treated animals was further 
determined by the Hargreaves method which 
uses radiant heat as a thermal stimulus applied 
to unrestrained animals.17 MBE (30, 100 and 
300  mg  kg-1) resulted in an increased paw with-
drawal latency corresponding to a decreased 
sensitivity to pain compared to the vehicle treated 
group. Inflammation-induced thermal hyperalgesia 
has been proposed to result from cytokine (tumour 
necrosis factor-α (TNF-α)) production followed 
by the induction of interleukins (IL-1β, IL-6 and 
Figure 5  Percentage DPPH scavenging activity 
against log concentration of extract and 
Gallic acid. [black squares = Gallic acid; 
black circles = MBE/extract]
Figure 6  Standard calibration curve for absorb-
ance of Gallic acid at concentration 
range of 500-7.8 µg mL-1
Figure 7  Increasing TAC with increasing 
concentration of MBE
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IL-8) and subsequent production of COX products 
such as PGE2 and sympathomimetic amines. These 
pro-inflammatory mediators cause an increased 
sensitivity of sensory neurons at the affected site to 
noxious thermal or mechanical stimuli.18 According 
to earlier studies, paw withdrawal response in 
inflammation-induced thermal hyperalgesia may 
be attenuated either by drugs that act peripherally 
(conventional COX-2 inhibitors) and/or spinally.19 
In previous phytochemical analysis, the stem 
bark of M. barteri was found to contain ellagic acid, 
3-O-methylellagic acid 4-O-β-D-ylopyranoside, 
3-O-methylellagic acid, gallic acid, methyl gallate, 
scopoletin and a polyoxygenated ellagitannin, 
macabarterin.9 The presence of some of these 
compounds may be responsible at least in part for 
the observed pharmacological effects. Ellagic acid is 
well known for its anti-inflammatory and anti-no-
ciceptive effects linked to its ability to decrease 
the levels of malondialdehyde (MDA), iNOS, and 
COX-2 in the oedema paw, subsequently attenuat-
ing the formation of cytokines (TNF-α, IL-1β), NO 
and PGE2 in the inflamed paw tissue.20 Macabarterin 
was found to inhibit the production of superox-
ides produced in a human neutrophil respiratory 
burst assay suggesting potential anti-inflammatory 
effect.9 The anti-inflammatory and anti-hyperalge-
sic effects of scopoletin is also well established and 
has been linked to the inhibition of PGE, TNF- α, 
IL-1β and IL-6 and suppression of the expression 
of COX-2.21 The demonstration of free radical scav-
enging ability and antioxidant capacity is consistent 
with previous works on the leaves of M. barteri.22
In the genus, Macaranga, M. peltata, M. conif-
era and M. denticulata have been reported to 
possess anti-inflammatory, anti-arthritic and 
 anti-nociceptive activities.23-25 The present results 
on M. barteri stem bark extract is the first evidence 
of its anti-inflammatory and anti-nociceptive 
activities and give scientific justification to its use 
in traditional medicine, complementing existing 
information on the pharmacological reports of the 
genus Macaranga.
CONCLUSION
The anti-inflammatory, anti-nociceptive and anti-
oxidant activity of M. barteri stem bark demon-
strated in this work is worth reporting. This report 
validates the stem bark of M. barteri as a potential 
anti-inflammatory and analgesic agent justifying its 
traditional uses in the treatment of painful inflam-
matory conditions. Investigation of its mechanisms 
of action, toxicity and other bioactive constituents 
are considered in further work. 
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